ReviewIntestinal research2017
Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease.
Review in Intestinal research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Management of Severe Behçet's Disease.Current rheumatology reports · 2026Review
- [Upper Gastrointestinal Involvement in Behcet's Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Article
- Behçet's disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan.Journal of gastroenterology · 2025Observational
- Optimal Treatment Approaches to Intestinal Behçet's Disease Complicated by Myelodysplastic Syndrome: The KASID and KSBD Multicenter Study.Yonsei medical journal · 2024Article
- Possible Association of Mutations in theJournal of clinical medicine · 2023Article
- Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy.Yonsei medical journal · 2023Article
- Immune-mediated inflammatory diseases of the gastrointestinal tract: Beyond Crohn's disease and ulcerative colitis.JGH open : an open access journal of gastroenterology and hepatology · 2022Review
- Behcet's Disease: An In-Depth Review about Pathogenesis, Gastrointestinal Manifestations, and Management.Inflammatory intestinal diseases · 2021Review
- Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational studyIntestinal research · 2021Article
- Behçet Disease: An Update for Dermatologists.American journal of clinical dermatology · 2021Review
- Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach.Frontiers in medicine · 2021Review
- Experimental Therapeutic Solutions for Behcet's Disease.Journal of experimental pharmacology · 2021Review
- Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet's disease.Zeitschrift fur Rheumatologie · 2020Article
- Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?Intestinal research · 2020Article
- Update on the treatment of Behçet's syndrome.Internal and emergency medicine · 2019Review
- Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.Gut and liver · 2018Review
- Small Bowel Lesions Mimicking Crohn's Disease.Current gastroenterology reports · 2018Review
- Cancer Risk in Patients with Intestinal Behçet's Disease: A Nationwide Population-Based Study.Gut and liver · 2018Article
- The outcomes and risk factors of early readmission in patients with intestinal Behçet's disease.Clinical rheumatology · 2018Article
- Updated treatment strategies for intestinal Behçet's disease.The Korean journal of internal medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is a chronic relapsing disease involving multiple organ systems. BD is characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. It is widely recognized that the presence of intestinal lesions may be a poor prognostic factor in intestinal BD, increasing the risk of surgery and decreasing the quality of life. Despite this, the management of intestinal BD has not been standardized. Empirical therapies including 5-aminosalicylic acid and corticosteroids have been used anecdotally to treat intestinal BD, but recent studies have provided evidence for the efficacy of anti-tumor necrosis factor α monoclonal antibodies. The development of agents targeting tumor necrosis factor α continues, it seems likely that they will change the therapeutic strategy and clinical outcomes of intestinal BD and inflammatory bowel disease. Monitoring disease activity such as endoscopic evaluation will become more important to obtain better outcomes. Here, we review current and future perspectives in the treatment and outcomes of intestinal BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.